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ABSTRACT
The objective of this study was to develop a formulation for propofol injection at various concentrations (1 and 2%) 
using palm oil-based nanoemulsion as the carrier. The nanoemulsions were characterised by globule size distribution 
(Dv 90 value), zeta potential, pH and viscosity determination. The physicochemical stability and accelerated stability 
of the formulations were also evaluated. Stability studies were performed for 6 months at 4, 16, 25 and 40oC storage 
temperatures. The propofol content was analysed by HPLC study. The characterisation result of propofol nanoemulsion 1 
and 2% showed good globule size distributions in Dv 90 values of 284 ± 1.15 nm and 304 ± 1.20 nm and also stable zeta 
potential values of-43.37 ± 0.96 mV and -40.97 ± 1.36 mV, respectively. Accelerated test showed that the formulations 
have excellent stability with no physical changes observed after centrifugation, autoclaving at 121oC for 15 mins, shaking 
for 12 hours and thermal cycling test. The stability studies indicated that propofol emulsion show good stability for 6 
months when stored at 4 ± 1oC and 16 ± 1oC based on Dv 90 values, zeta potential, and pH readings. No changes in 
propofol concentrations were observed after 6 months storage. Overall, propofol in palm oil-based nanoemulsions as 
carrier was found to be stable and can be used as an alternative anaesthetic injection.
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ABSTRAK
Penyelidikan ini bertujuan untuk membangun satu formulasi suntikan Propofol dengan mengguna nanoemulsi berasas 
minyak sawit pada berbagai kepekatan (1 dan 2%) sebagai pembawa. Evaluasi ke atas size globul, potensial zeta, pH 
dan kelikatan dilakukan kepada formulasi nanoemulsi. Profil kestabilan fizikokimia dan kestabilan dipercepatkan juga 
ditentukan. Kajian kestabilan dilakukan selama 6 bulan pada suhu 4, 16, 25 dan 40oC. Pemeriksaan kandungan propofol 
dilakukan dengan menggunakan kajian kromatografi cecair prestasi tinggi. Hasil evaluasi terhadap nanoemulsi propofol 
(1 dan 2%) menunjukkan sebaran globul saiz Dv 90 masing-masing ialah 284 ± 1.15 nm dan 304 ± 1.20 nm dan nilai 
potensial zeta yang stabil (-43.37 ± 0.96 mV dan -40.97 ± 1.36 mV). Ujian dipercepatkan seperti kajian penggoncangan 
selama 12 jam, proses autoklaf pada suhu 121oC selama 15 minit, proses pengemparan dan juga proses kajian penyimpanan 
pada suhu berbeza menunjukkan formulasi nanoemulsi yang stabil tanpa perubahan sifat fizikal. Kajian kestabilan juga 
menunjukkan formulasi nanoemulsi yang stabil berdasarkan nilai Dv 90, potensi zeta, dan pH apabila ianya disimpan 
pada suhu 4 dan 16oC selama 6 bulan. Formulasi nanoemulsi juga menunjukkan kestabilan ke atas kandungan propofol 
selepas disimpan selama 6 bulan. Keseluruhan, nanoemulsi berasas minyak sawit menunjukkan formula yang stabil dan 
boleh dijadikan sebagai medium penghantar alternatif bagi propofol.
Kata kunci: Nanoemulsi; propofol; minyak sawit; trigliserida rantai sederhana; kestabilan
INTRODUCTION
Determination of an appropriate drug carrier is one of the 
main problems in pharmaceutical development especially 
for a drug which is slightly soluble in water. The ideal 
criteria for an appropriate carrier should be that it is 
non-toxic and able to increase the efficacy of the active 
compound which it is carrying. Lipid emulsion is one of the 
popular and potential carriers for drugs which are slightly 
soluble in water (Kawakami et al. 2000). Lipid emulsion 
are used as a source of calories for non-ambulatory patients 
due to its stability and non-toxic nature. Its potential to be 
used as vehicle for drug delivery was realised in the late 
nineties (Floyd 1999).
Nanoemulsions have various advantages as a drug 
delivery system since they are found to be non-toxic, non-
irritant and are not harmful towards human and animal 
cells (Shah et al. 2010; Aboofazeli 2010). The use of 
nanoemulsions can eliminate the bad taste from the drug, 
reduce drug toxicity and increase stability of light sensitive 
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6drugs (Sukanya et al. 2013). Nanoemulsion has been 
successfully used in cosmetic products and food technology 
as well as a drug carrier system (Gutierrez et al. 2007).
Propofol (2, 6-diisopropylphenol) is a drug which is 
commonly used to induce or maintain anaesthesia in the 
intensive care unit and in procedures involving outpatient 
care (Peterson et al. 2003; Baker and Mohamed 2005). Its 
positive characteristics include rapid onset, short duration 
of action and minimal side effects. In the current market, 
soybean oil is used as the oil source in the production of 
propofol emulsion (Date & Nagarsenker 2008).
Palm oil is one of the sources of long chain triglycerides 
(LCT) similar to soybean oil. Palm oil is obtained from the 
mesocarp of Elaeis guineensis. Malaysia and Indonesia 
account for 83 percent of palm oil production and 89 
percent of global exports (Imoisi et al. 2015). Utilisation 
of palm oil in pharmaceutical preparations is still not 
fully explored (Zainol et al. 2012). Although a number of 
researchers have developed propofol formulations, there 
is no report about any development of a propofol injection 
using palm oil as one of the major ingredients. This study 
was conducted with the aim of developing a propofol 
injection using palm oil-based nanoemulsion or NEMS™ 
(Nanoemulsion Minyak Sawit) as the carrier.
Palm oil is relatively stable to free radical oxidation 
as compared to soybean oil. Natural antioxidants and high 
contents of monounsaturated fatty acids (such as oleic 
acid) as well as saturated fatty acids which are found in 
palm oil are the main contributing factors to its stability 
against free radical oxidation. Polyunsaturated oils such as 
soybean shows a relatively poor stability since it is easily 
oxidised, isomerised and polymerised (Ong 2002). Palm oil 
contains vitamin E, especially tocopherols and tocotrienol 
(Maarasyid et al. 2014). These natural antioxidants can 
delay the oxidation of the palm oil-based emulsions (Edem 
2002), thus it may increase the stability of the propofol 
formulation under high temperature especially during 
the sterilisation process. The addition of middle chain 
triglyceride (MCT) (from coconut oil) to the formulation 
increases the metabolism of the fatty acids and reduces the 
toxicity of long chain triglyceride (LCT) found in palm oil 
(Jumaa & Muller 2001).
The present study focused on the evaluation of the 
physical characterisation and stability of propofol in palm 
oil-based nanoemulsion. Parameters of stability measured 
were globule size distribution, pH, and zeta potential value 
in normal storage condition and in various temperatures 
for 6 months. Stability profile in accelerated test conditions 
was also determined. The analysis of propofol content in 
the nanoemulsion was also conducted.
MATERIALS AND METHODS
MATERIALS
Palm Oil (refined palm olein) was obtained from local 
cooking oil (Seri Murni, FFM Sdn Bhd, Malaysia). Palm 
olein is one of the fractionation products from palm oil 
which has been refined, bleached and deodorized (RBD). 
MCT oil was purchased from Enersos (Pharma Sdn Bhd, 
Malaysia). Pure propofol, sodium hydroxide, glycerol 
and sodium oleic were purchased from Sigma-Aldrich 
Germany. Lipoid E-80® (egg lecithin) was purchased from 
GmbH, Germany. Diprivan®, a soybean-based propofol 
injection was supplied by Astra Zeneca Macclesfield, 
UK. Double distilled water was used for all preparations. 
Chemicals for high-pressure liquid chromatography 
(HPLC) were of HPLC grade and all other chemicals were 
of analytical grade.
PREPARATION OF PROPOFOL NANOEMULSIONS
The coarse emulsion was prepared by mixing propofol and 
an emulsifier (Lipoid E-80®) in an oil mixture consisting 
of palm oil and MCT oil. The mixture was then heated 
at 70oC to obtain a clear oil phase. The aqueous phase 
consisting of glycerol as a co-surfactant and sodium 
oleate as stabilizer were heated to 70oC and agitated until 
uniformly dissolved. The oil phase was then gently added 
to the aqueous phase with high speed shear mixing initiated 
using a homogeniser (Ultra Turrax® IKA) at 10,000 rpm 
for 6 mins to obtain the coarse emulsion. The propofol 
nanoemulsion was subsequently prepared by passing the 
coarse emulsion through a high-pressure homogenizer 
(APV 2000, Denmark) at 600 bar for eight cycles to get 
the final emulsion. The pH was adjusted to 8.7 ± 0.1 with 
NaOH 0.1 N. Finally, the nanoemulsion was transferred 
to vials which were then purged with nitrogen gas, sealed 
and sterilized by autoclaving (Hirayama, Japan) at 121oC 
for 15 minutes. The composition of different formulations 
of propofol nanoemulsion is shown in Table 1.
TABLE 1. Composition of different formulation of propofol 
nanoemulsion
   Ingredients Propofol 1% Propofol 2%
 in NEMS™/g in NEMS™/g
Propofol 1 2
Oil Phase (Palm oil 10 10
 and MCT)
Lipoid E-80® 1.2 1.2
Glycerol 2.5 2.5
Sodium oleate 0.01 0.01
Water for injection until 100 100
CHARACTERISATION OF PROPOFOL NANOEMULSIONS
The globule size distribution of the propofol nanoemulsion 
was measured by laser diffraction using Mastersizer 2000 
(Malvern Instruments Ltd., UK). Prior to measurement, 
samples (± 2 mL) were diluted with water to ± 800 mL. 
Measurements were made in triplicate. Zeta potential 
of propofol nanoemulsion droplets was measured using 
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7the Zetasizer Nano-ZS (Malvern Instruments Ltd., 
UK). Samples were first diluted (1:150) with water and 
transferred to disposable cuvettes. Results used were 
the average of three measurements. Determination of 
pH was made using a pH meter (Mettler-Toledo GmbH, 
Switzerland). The electrode was thoroughly rinsed after 
every individual sample in order to avoid errors due to oil 
contamination of the electrode. The viscosity of propofol 
nanoemulsions (6.7 mL sample) was determined undiluted 
at 25oC using Brookfield Digital Rheometer (Model DVIII, 
Brookfield Engineering Laboratories Inc., USA) utilising 
the SC4-18 spindle. Viscosity values were analysed using 
Rheocalc V3.1-1 software. 
ACCELERATED STABILITY TESTS
Centrifugation was performed at 3800 rpm/60 min in 
ambient temperature using the Hettich Zentrifugen 
Universal 32R (Germany) centrifuge. Autoclaving process 
was conducted using an autoclave (Hirayama, Japan) set 
at 121oC for 15 min. 
Shaking test and thermal cycling test were performed 
as previously described (Han et al. 2001). Shaking test 
was done by using samples in unopened containers which 
were shaken using Unitronic OR (Spain) at 100 strokes 
per minutes in room temperature for 2, 4, 6, 8, 10, and 
12 hours. 
 Thermal cycling test was conducted by incubating the 
nanoemulsion in a Pro-tech incubator (Malaysia) at 30°C 
for 8 hours and followed by cooling at 4–8°C for 16 hours. 
This cycle was repeated daily and samples were withdrawn 
at 7, 14, and 21 days. Globule size was determined using 
the Mastersizer 2000 (Malvern Instruments Ltd., UK). All 
experiments were performed in triplicate.
STABILITY TEST
Stability of the nanoemulsion was assessed by monitoring 
the changes in globule size, zeta potential and pH of the 
nanoemulsion at normal storage condition (4oC). Data 
was taken every week for 24 weeks. Stability tests were 
conducted on samples stored at various temperatures (i.e. 
16, 25 and 40oC). Tests were conducted at time intervals 
of 0 h, 1, 3 and 6 months.
APPARATUS AND CHROMATOGRAPHIC CONDITION
The HPLC analysis was performed using the Waters 
Associates (Waters Corp., Milford, MA) HPLC system. 
The system consisted of a controller (Waters 600), in-line 
degasser, an auto sampler (Waters 2707) and a photodiode 
array detector (Waters 2998). Separation was achieved with 
a reversed phase ODS symmetry C18 (15 cm × 4.6 mm; 5 
µm globules) column. Mixture of methanol and deionised 
water (80:20) was used as the mobile phase. Flow rate of 1 
mL/min was maintained and the wavelength for detection 
was 276 nm.
ANALYSIS OF TOTAL PROPOFOL CONTENT
The concentration of propofol in each sample was 
determined with a constructed calibration curve with 
the concentration range between 100 to 500 µg/mL. The 
propofol standard was dissolved with methanol and filtered 
through a 0.45 µm membrane and transferred to the HPLC 
vials. The method on sample preparation was adapted 
from a previous study by Babl (1995). An amount of 100 
µL of nanoemulsion was diluted to 5 mL using methanol 
as diluent and filtered through a 0.45 µm membrane. The 
filtrates (10 µL) were then subjected to HPLC analysis to 
estimate the amount of propofol in nanoemulsion. 
STATISTICAL ANALYSIS
All the data were analysed using Statistically Package for 
Social Sciences (SPSS) version 16.0. Data were analyzed 
using independent group t-test to compare the value of 
sample with standard. Data were presented as average 
value and standard deviation (SD). All experiments were 
done in triplicate. The differences were considered to be 
significant at level of p ≤ 0.05.
RESULTS AND DISCUSSION
In this study, the mixture of palm oil and MCT (from coconut 
oil) was used as the oil phase for the nanoemulsion. This 
mixture exhibited a very good physical parameters such 
as globule size distribution, pH and zeta potential value 
as compared to the commercially available Diprivan® 1% 
(Astra-Zeneca, United Kingdom). Palm oil is commonly 
used as cooking oil (Ahmad et al. 1996) and as an adjuvant 
for food preparations (Mukherjee & Analava 2009). 
Intravenous administration of palm oil-based nanoemulsion 
in combination with MCT from coconut oil has been shown 
to be non-toxic in rabbits (Jufri et al. 2012). Palm oil can 
be considered as one of the most versatile vegetable oils 
(Ahmad et al. 1996) and it has a great potencial to be used 
pharmaceutical product development. Egg lecithin was 
chosen for development of propofol nanoemulsion as they 
are shown to be non-toxic (Wabel 1998), natural and has 
been used in parenteral products. This surfactant could 
form a stable emulsion without any separation even after 
the autoclaving process (Yamaguchi et al. 1995).
In this study, Diprivan® 1% was chosen as a standard 
and compared with propofol formulation that consists of 
palm oil and MCT oil. Diprivan® 1% contains propofol 
and is known as the original formulation. This formula is 
composed of a fat emulsion consisting of 10% soybean 
oil containing long-chain triglycerides (LCTs) (Le Guen 
et al. 2014).
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8CHARACTERISATION OF THE PROPOFOL 
NANOEMULSION
The globule size measurements of propofol nanoemulsion 
showed slightly higher values when compared to Diprivan®, 
as shown in Table 2. Size measurements established are 
acceptable for a parenteral product. The acceptable 
droplet diameter range for a nanoemulsion is between 50-
1000 nm, but the common size range targeted is usually 
between 100-500 nm (Shah et al. 2010). In this study, laser 
diffractometry method was used to analyse globule size 
distribution of the nanoemulsion. This method provides 
information on the percentage of globule size distribution 
of the nanoemulsions. The Dv 50 value describes the 
particle size below which 50% of the volume of droplets 
exists and the Dv 90 shows particle size below which 90% 
of the volume of droplets exists.
potential in the range of between -30 to -50 mV and with 
pH range of 6–9 represents a stable value for an emulsion 
(Luk & Tian 2007; Driscol et al. 2001). The pH readings 
for all propofol nanoemulsions in this study were more than 
7 (Table 3). It is within the requirement for intravenous 
formulation in which it should ideally be neutral, but can 
reside within the range of 4–9 (Liu 2008). It has been 
reported that emulsions with pH in this range will reduce 
the possibility of hydrolysis to the emulsifying agent in 
the emulsion (Floyd 1999). Emulsion with phospholipids 
will be stable in an alkaline medium (Peeters et al. 2004). 
The viscosity value showed that there were no significant 
different on viscosity value between propofol 1% and 
2% when compared to Diprivan® 1% (Table 4). All of 
data showed that the rheology of the emulsion followed 
Newtonian principle.
Zeta potential of 1 and 2% propofol nanoemulsions 
measured were -43.37 ± 0.96 mV and -40.97 ± 1.36 mV, 
respectively (Table 3). The result showed that the propofol 
nanoemulsions were stable and in agreement with previous 
work. Floyd (1999) reported that the emulsion with pH 
more than 7 would usually have a zeta potential value 
between -40 to -50 mV. It has been reported that the zeta 
TABLE 3. Zeta potential and pH value of propofol in NEMS™ 
compared with Diprivan® 1% (n = 3)
  Formulations  Zeta Potential/mV pH
Propofol 1% in NEMS™ -43.37±0.96 7.32±0.02
Propofol 2% in NEMS™ -40.97±1.36 7.52±0.02
Diprivan® 1% -43.30±1.93 7.66±0.02
TABLE 4. Viscosity of propofol in NEMS™ compared with 
Diprivan® 1% (n = 3)
  Formulations Viscosity/cps
Propofol 1% in NEMS™ 1.61±0.07
Propofol 2% in NEMS™ 1.73±0.11
Diprivan® 1% 1.69±0.06
TABLE 5. Effect of storage time at various temperature for 6 months on Dv 90 (nm), zeta potential (mV), and pH value (n = 3)
 
Time
 Dv 90/nm Potential Zeta/mV pH
 16oC 25oC 40oC 16oC 25oC 40oC 16oC 25oC 40oC
Propofol 0 month 284.3±1.0 284.3±1.0 284.3±1.0 -43.4±0.96 -43.4±0.96 -43.4±0.96 7.32±0.02 7.32±0.02 7.32±0.02 
1% in 1 month 285.6±0.6 283.0±1.2 288.0±1.0 -44.3±0.49 -49.2±1.25 -42.4±0.30 7.31±0.01 7.29±0.01 7.09±0.01
 2 month 288.0±1.7 293.0±2.4 297.6±1.5 -43.5±0.72 -38.2±0.96 -48.3±0.44 7.30±0.01 7.24±0.01 6.93±0.01
NEMS™ 3 month 289.3±0.6 292.0±1.0 299.3±1.5 -43.3±0.36 -47.0±2.11 -39.6±1.36 7.30±0.02 7.18±0.01 6.69±0.02
 6 month 285.3±1.0 289.0±2.6 295.0±4.3 -41.4±1.76 -39.7±3.11 -39.5±0.67 7.26±0.01 6.91±0.01 6.36±0.01
Propofol 0 month 304.3±0.6 304.3±0.6 304.3±0.6 -40.9±1.36 -40.9±1.36 -40.9±1.36 7.52±0.02 7.52±0.02 7.52±0.02 
2% in 1 month 303.3±0.6 297.7±1.0 299.6±1.5 -40.9±0.60 -38.3±0.84 -56.7±0.35 7.50±0.01 7.49±0.01 7.17±0.01 
 2 month 306.6±1.2 305.3±0.6 309.3±1.5 -44.4±0.55 -37.9±0.24 -40.9±1.94 7.47±0.01 7.31±0.01 6.99±0.01
NEMS™ 3 month 308.0±1.0 308.3±1.0 318±2.2 -43.7±0.42 -42.8±1.48 -51.8±1.80 7.44±0.02 7.02±0.01 6.80±0.02
 6 month 304.6±2.5 310.3±1.5 309±1.0 -42.8±1.48 -47.4±1.22 -54.7±0.96 7.42±0.01 6.84±0.01 6.45±0.01
TABLE 2. Globule size distribution of propofol in NEMS™ 
compared with Diprivan® 1% (n = 3)
 Laser Difractometry
         Formulations Globule Size Distribution/nm 
 Dv 50 Dv 90 Uniformity
Propofol 1% in NEMS™ 193±0.60 284±1.15 0.24±0.01
Propofol 2% in NEMS™ 198±1.00 304±1.20 0.26±0.01
Diprivan® 1% 188±0.60 269±1.00 0.24±0.01
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9ACCELERATED TEST
The results showed that there were no physical changes 
observed after centrifugation and autoclaving (Figure 
1). The formula had good stability over 12 hours for the 
shaking test and over 21 days for thermal cycling test 
without any significant changes in globule size (p > 0.05) 
as shown in Figure 2 and 3. 
The accelerated test was performed in order to ensure 
and evaluate the stability of freshly prepared propofol 
emulsions when stored in extreme conditions. The purpose 
of centrifugation was to compare the globule size before 
and after pressure was added to the system in which 
centrifugation can lead to phase separation in unstable 
emulsion system (Restu et al. 2015). Autoclaving test was 
conducted to evaluate the influence of high temperature 
on the formulations especially for products which require 
sterilization. It is important for an intravenous emulsion 
to be stable after the standard sterility process (Jumaa 
& Muller 1999). There was no significant difference 
in globule size of the formulations, while the pH value 
decreased. This can be due to the release of the free fatty 
acid in emulsion from oil phase or emulsifying agent. But 
the product still fulfilled the requirement for pH limits. 
Shaking test was done to enhance the interaction of each 
globule in emulsion and to investigate the stability of 
emulsion (Han et al. 2001). Whereas thermal cycling test 
was done to determine the stability of emulsions when 
stored in a place with fluctuating temperatures. 
TABLE 6. Propofol content of propofol in NEMS™ compared 
with Diprivan® 1% (n = 3)
  Formulations Concentration of  % Recovery
 propofol/mgmL-1 
Propofol 1% in NEMS™  10.09±0.04 100.90
Propofol 2% in NEMS™ 20.05±0.15 100.24
Diprivan® 1% 10.08±0.05 100.08
FIGURE 1. Dv 90 (nm) of the emulsions by laser diffractometry after centrifugation and autoclaving process (n = 3)
FIGURE 2. Dv 90 (nm) diameter of emulsions by laser diffractometry as a function of shaking time (n = 3)
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STABILITY TEST
In this study, formulations were stored at 4oC (refrigerated) 
for 6 months as intravenous emulsions are commonly 
stored at this temperature. The stability data established 
in this study showed that the propofol nanoemulsions 
developed were stable when stored at 4oC (Figure 4, 5 
and 6). There were no significant difference (p > 0.05) 
for globule size, zeta potential and pH values of propofol 
nanoemulsions over a storage period of 6 months. Stability 
of the nanoemulsions when stored at various temperatures 
showed there were no significant difference on globule 
size, zeta potential and pH values when stored at 16oC. 
However, pH was reduced when stored at 25oC and 40oC 
(Table 5).
Stability of the dosage form is an important issue 
when nanoemulsions are to be used as drug carriers. The 
stability of the nanoemulsion during storage will ensure 
the content of the pharmaceutical active ingredient (i.e. 
propofol) in the dosage form is not compromised. The 
presence of natural antioxidants in palm oil may be the 
factor that enhances the stability of this vegetable oil-based 
nanoemulsion. Interestingly, palm oil has a high content of 
vitamin E in the forms of both tocopherol and tocotrienol 
with an unsaturated side chain that is not commonly found 
in other vegetable oils. Tocopherol is also less volatile 
such that it is able to persistently delay oxidation even in 
high temperatures (Imoisi 2015). Changes in globule size 
distribution and the zeta potential value when an emulsion 
is exposed to various conditions such as temperature 
will give a reliable picture of the stability profile of the 
emulsion. 
The evaluation of the stability data showed that the 
physical character of the propofol nanoemulsions did 
not undergo any significant change during storage for 6 
months in different storage conditions. However, there was 
a change in pH of the emulsion when stored at 25oC and 
40oC. It might be due to hidrolysis process of egg lecithine 
and oil from the emulsions.when exposed to temperatures 
FIGURE 3. Dv 90 diameter of emulsions by laser diffractometry as a function of thermal cycling time (n = 3)
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FIGURE 4. Effect of storage time (4°C) for 24 weeks on Dv 90 (nm) of propofol 1% and 2% in NEMS™ (n = 3)
300
Propofol 1%  in NEMS Propofol 2% in NEMS
D
v 
90
/n
m
320
310
2 8 20
270
290
280
260
0 1 43 1612 24
Time/Weeks
JSKM16(2) 2.indd   10 24/04/2018   9:16:01 AM
11
above room temperature. High temperatures will change 
the phospatydil choline and phospatidyl ethanol amine into 
the lyso form and thus reduces the pH of the emulsions 
(Jiao & Diane 2005).
DRUG ANALYSIS
The aim of this test was to detemine the total propofol 
content in the nanoemulsion. The results showed that all 
of the propofol in NEMS™ formulations showed good 
recovery (Table 6). It is recommended that the content of 
propofol in an emulsion should be in the range of 98% to 
102% (The United States Pharmacopeia 30, 2007). This 
FIGURE 6. Effect of storage time (4°C) for 24 weeks on zeta potential and pH value of Propofol 2% in NEMS™ (n = 3)
FIGURE 5. Effect of storage time (4°C) for 24 weeks on zeta potential and pH value of Propofol 1% in NEMS™ (n = 3)
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is very important to ensure that the dose is not clinically 
compromised and the propofol injection would give a 
maximal effect to patients.
CONCLUSION
The propofol nanoemulsions developed in this study 
demonstrated no change in physical stability when 
stored at room temperature for more than 6 months. 
The nanoemulsions were also stable after exposure to 
autoclaving process at 121oC for 15 min, centrifugation 
and shaking test for 12 hours. No changes in propofol 
pH
pH
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content of the nanoemulsions were found when kept at 
4 and 16oC for 6 months. In conclusion, the intravenous 
propofol nanoemusion of 1 and 2% in palm oil-based 
nanoemulsion in combination with MCT oil (NEMS™) are 
stable and can be considered to be used as an alternative 
anaesthetic injection.
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